ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...
One of the most recognized features of No Child Left Behind is subgroup analysis, which shifted attention from the average performance of a school to the performance of specific populations within a ...
In the dynamic world of clinical trials, innovative methods are vital to improving the efficiency and reliability of medical research. One area that has garnered both interest and scepticism is ...
Delcath Systems (DCTH) announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication was published in ...
Recent studies highlight the effectiveness of lenvatinib and pembrolizumab in improving overall survival for patients with ...
Author(s)Goadsby PJ, Reuter U, Hallströ, m Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377(22):2123-2132. doi: 10.1056/NEJMoa1705848. Certain medications ...
This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.” Clinical trials of newly developed drugs often don’t ...
Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study. Ryan Haumschild, PharmD, MS, MBA: Can you please review the rationale and study design of the 5-year ...
– Cabozantinib reduced the risk of disease progression or death by 50 percent compared with placebo in patients with advanced gastrointestinal neuroendocrine tumors – – Supplemental New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback